J. Coehlo

Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial

L. Korbee, B. Trapnell, B. V. Van Tassell, 2021, The Lancet Rheumatology.